Buscar
Mostrando ítems 41-50 de 3351
Advances in sickle cell disease treatment: From drug discovery until the patient monitoring
(2011-04-01)
Sickle Cell Disease (SCD) is one of the most prevalent hematological diseases in the world. Despite the immense progress in molecular knowledge about SCD in last years few therapeutical sources are currently available. ...
Advances in sickle cell disease treatment: From drug discovery until the patient monitoring
(2011-04-01)
Sickle Cell Disease (SCD) is one of the most prevalent hematological diseases in the world. Despite the immense progress in molecular knowledge about SCD in last years few therapeutical sources are currently available. ...
An integrated device for magnetically-driven drug release and in situ quantitative measurements: design, fabrication and testing
(Elsevier Science, 2015-03)
We have developed a device capable of remote triggering and in situ quantification of therapeutic drugs, based on magnetically-responsive hydrogels of poly (N-isopropylacrylamide) and alginate (PNiPAAm). The heating ...
Pharmacokinetic properties and in silico ADME modeling in drug discovery
(Bentham ScienceBussum, 2013-03)
The discovery and development of a new drug are time-consuming, difficult and expensive. This complex process has evolved from classical methods into an integration of modern technologies and innovative strategies addressed ...
Shikimate kinase: A potential target for development of novel antitubercular agents
(Bentham Science Publ Ltd, 2007-03-01)
Tuberculosis (TB) remains the leading cause of mortality due to a bacterial pathogen, Mycobacterium tuberculosis. However, no new classes of drugs for TB have been developed in the past 30 years. Therefore there is an ...
Drug leads for interactive protein targets with unknown structure
(Elsevier, 2016-04)
The disruption of protein?protein interfaces (PPIs) remains a challenge in drug discovery. The problem becomes daunting when the structure of the target protein is unknown and is even further complicated when the interface ...
The Thiol-polyamine Metabolism of Trypanosoma cruzi: Molecular Targets and Drug Repurposing Strategies
(Bentham Science Publishers, 2018-09)
Chagas´ disease continues to be a challenging and neglected public health problem in many American countries. The etiologic agent, Trypanosoma cruzi, develops intracellularly in the mammalian host, which hinders treatment ...
Structure-based drug design studies on a series of aldolase inhibitors
(Sociedade Brasileira de Química - SBQSão Paulo, 2013)
Human African trypanosomiasis, also known as sleeping sickness, is a major cause of death in Africa, and for which there are no safe and effective treatments available. The enzyme aldolase from Trypanosoma brucei is an ...
Highlighting the impact of chitosan on the development of gastroretentive drug delivery systems
(2020-09-15)
The development of gastroretentive systems have been growing lately due to the high demand for carriers that increase drug bioavailability and therapeutic effectiveness after oral administration. Most of systems reported ...